Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nanomedicine ; 7(2): 153-61, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21034859

RESUMO

Multicompartment nanoscopic carriers can be easily assembled by inducing the aggregation of anionic "hybrid" niosomes by means of cationic biocompatible polyelectrolytes. The resulting vesicle clusters, whose size and overall net charge can be easily controlled by varying the polyelectrolyte-to-particle charge ratio, show an interesting potential for multidrug delivery. In this article we provide strong evidence for their effective use in vitro as multicompartment vectors selectively directed toward monocyte/macrophage cells, showing that the monocyte/macrophage-mediated activation of Tγδ lymphocytes induced by zoledronic acid is enhanced by a factor 10(3) when the zoledronic acid is intracellularly delivered through these carriers. Furthermore, the multicompartment ɛ-polylysine niosome clusters, with their intrinsic selectivity toward macrophages, appear particularly suitable for implementing therapeutic strategies against chronically infected macrophages. FROM THE CLINICAL EDITOR: ɛ-polylysine niosome clusters, with their intrinsic selectivity toward macrophages, offer the potential for multidrug delivery. The effectiveness of aminobisphosphonate zoledronate is demonstrated to enhance the recruitment of Tγδ lymphocytes by macrophages by 2 orders of magnitude, suggesting a new therapeutic strategy for addressing pathologies featuring chronically infected macrophages.


Assuntos
Conservadores da Densidade Óssea/administração & dosagem , Difosfonatos/administração & dosagem , Imidazóis/administração & dosagem , Ativação Linfocitária/efeitos dos fármacos , Linfócitos T/metabolismo , Conservadores da Densidade Óssea/metabolismo , Difosfonatos/metabolismo , Humanos , Imidazóis/metabolismo , Leucócitos/metabolismo , Lipossomos , Macrófagos/metabolismo , Nanomedicina , Polilisina/química , Polilisina/metabolismo , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Ácido Zoledrônico
2.
Nutrition ; 25(11-12): 1157-68, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19592219

RESUMO

OBJECTIVE: The aim of this study was to investigate the development of non-alcoholic fatty liver disease (NAFLD) in response to a high-fat diet in rats and to test the hypothesis that dietary coenzyme Q monomethyl ether (CoQme) has antisteatogenic effects. METHODS: Rats were fed a standard low-fat diet (control) for 18 wk or a diet containing 35% fat (57% metabolizable energy) for 10 wk, then divided into three groups for the following 8 wk. One group was given CoQ9me (30mg/kg body weight per day in 0.3mL olive oil: high fat+CoQ9me), the second olive oil (0.3mL/d) only (high fat + olive oil), and the third group received no supplements (high fat). RESULTS: Insulin levels and the activity of alanine aminotransferase in the plasma were significantly increased in all high-fat diet groups, and the homeostasis model assessment of insulin resistance indicated insulin resistance. Triacylglycerol concentrations in whole plasma and in very low-density lipoprotein and low-density lipoprotein fractions were also raised. Liver histology showed lipid accumulation in animals fed the high-fat diets, and liver triacylglycerol levels were increased (2.5- to 3-fold) in all high-fat diet groups. These effects were not changed by the administration of CoQ9me. CONCLUSIONS: Rats fed a diet with 57% energy from fat showed insulin resistance, hypertriglyceridemia, increased very low-density lipoprotein production, hepatic steatosis, and liver damage, and thus provide a good model for the early stages of NAFLD. Dietary CoQ9me, however, did not ameliorate the damaging effects of the high-fat diet.


Assuntos
Gorduras na Dieta/efeitos adversos , Fígado Gorduroso/prevenção & controle , Resistência à Insulina , Metabolismo dos Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Ubiquinona/uso terapêutico , Alanina Transaminase/sangue , Animais , Dieta com Restrição de Gorduras , Gorduras na Dieta/administração & dosagem , Fígado Gorduroso/sangue , Fígado Gorduroso/etiologia , Hipertrigliceridemia/etiologia , Insulina/sangue , Lipídeos/sangue , Fígado/patologia , Masculino , Éteres Metílicos/farmacologia , Éteres Metílicos/uso terapêutico , Ratos , Ratos Wistar , Ubiquinona/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA